Medicaid Pharmacy and Therapeutics Committee Agenda for June 14, 2007
The Pharmacy & Therapeutics Committee will meet June 14, 2007, from 8:45 a.m. to 3:30 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York
Agenda Items
1. Review of the Ophthalmic Prostaglandin Agonists therapeutic class for inclusion to the Preferred Drug Program.
Description: The Committee will review the following drugs to determine preferred and non-preferred status.
Drugs Affected: Lumigan (bimatoprost), Travatan (travoprost), Travatan Z (travoprost), Xalatan (latanoprost).
2. Review of the Selective Alpha Adrenergic Blockers therapeutic class (used in the treatment of Benign Prostatic Hyperplasia) for inclusion to the Preferred Drug Program.
Description: The Committee will review the following drugs to determine preferred and non-preferred status.
Drugs Affected: Flomax (tamsulosin), Uroxatral (alfuzosin).
3. Review of the Cyclooxygenase II (COX II) Inhibitors therapeutic class for inclusion to the Preferred Drug Program.
Description: The Committee will review the therapeutic class to determine whether the class should be included in the Preferred Drug Program.
Drugs Affected: Celebrex (celecoxib).
4. Review of the Central Nervous System (CNS) Stimulants therapeutic class for inclusion to the Preferred Drug Program.
Description: The Committee will review the following drugs to determine preferred and non-preferred status.
Drugs Affected: Adderall (amphetamine salt combo), Adderall XR (amphetamine salt combo XR), amphetamine salt combo, Concerta (methylphenidate), Cylert (pemoline), Daytrana (methylphenidate), Desoxyn (methamphetamine), Dexedrine (dextroamphetamine sulfate), Dexedrine Spansule (dextroamphetamine), dextroamphetamine sulfate, dextroamphetamine sulfate SA, Dextrostat (dextroamphetamine sulfate), Focalin (dexmethylphenidate), Focalin XR (dexmethylphenidate XR), Metadate CD (methylphenidate CD), Metadate ER (methylphenidate ER), Methylin ER (methylphenidate ER), Methylin (methylphenidate), methylphenidate, methylphenidate ER, pemoline, Provigil (modafinil), Ritalin (methylphenidate), Ritalin SR (methylphenidate SR), Ritalin LA (methylphenidate LA).
5. Review of the Urinary Tract Antispasmodics therapeutic class for inclusion to the Preferred Drug Program.
Description: The Committee will review the following drugs to determine preferred and non-preferred status.
Drugs Affected: Detrol (tolterodine), Detrol LA (tolterodine LA), Ditropan (oxybutynin), Ditropan XL (oxybutynin XL), Enablex (darifenacin), oxybutynin, oxybutynin ER, Oxytrol (oxybutynin), Sanctura (trospium), Vesicare (solifenacin).
Schedule (subject to change based on meeting proceedings)
| Agenda Time Line | |
|---|---|
| 8:45 - 9:00 | Welcome and Introductions |
| 9:00 - 10:00 | Public Comments from interested parties* |
| 10:00 - 10:15 | Break |
| 10:15 - 10:45 | Clinical Review of Ophthalmic Prostaglandin Agonists |
| 10:45 - 11:15 | Clinical Review of Selective Alpha Adrenergic Blockers |
| 11:15 - 11:45 | Clinical Review of COX II Inhibitors |
| 11:45 - 12:45 | Lunch Break/Executive Session (evaluation of trade secret supplemental rebate information) |
| 12:45 - 1:00 | Final Recommendations for Preferred Drugs (Ophthalmic Prostaglandin Agonists, Alpha Adrenergic Blockers and COX IIs) |
| 1:00 - 1:30 | Clinical Review of Central Nervous System (CNS) Stimulants |
| 1:30 - 2:00 | Clinical Review of Urinary Tract Antispasmodics |
| 2:00 - 2:15 | Election of Committee Chair and Co-Chair |
| 2:15 - 2:45 | Break/Executive Session (evaluation of trade secret supplemental rebate information) |
| 2:45 - 3:00 | Final Recommendations for Preferred Drugs (CNS Stimulants and Urinary Tract Antispasmodics) |
| 3:00 - 3:15 | Topical Immunomodulator DUR Status Report |
| 3:15 - 3:30 | DOH Update, Final Comments and Adjournment |
*Interested parties must notify DOH at least 1 week in advance of their request to speak during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed one (1) hour. All written comments regarding topics before the Committee must be received at least 1 week in advance of the meeting. Written comments should summarize key points and may not exceed two (2) pages in length.
NOTE: Those wishing to submit clinical studies or clinical reports, rather than comments, must submit the study/report at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material.
Posted May 14, 2007
